51 related articles for article (PubMed ID: 38444271)
1. Survival Outcomes of Patients with Mycosis Fungoides Involving the External Ear and Ear Canal.
Wilkinson AJ; Nader ME; Roberts D; Duvic M; Gunther JR; Dabaja BS; Gidley PW
Laryngoscope; 2023 Jun; 133(6):1486-1491. PubMed ID: 36054317
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.
Fléchon L; Arib I; Dutta AK; Hasan Bou Issa L; Sklavenitis-Pistofidis R; Tilmont R; Stewart C; Dubois R; Poulain S; Copin MC; Javed S; Nudel M; Cavalieri D; Escure G; Gower N; Chauvet P; Gazeau N; Saade C; Thiam MB; Ouelkite-Oumouchal A; Gaggero S; Cailliau É; Faiz S; Carpentier O; Duployez N; Idziorek T; Mortier L; Figeac M; Preudhomme C; Quesnel B; Mitra S; Morschhauser F; Getz G; Ghobrial IM; Manier S
Blood Adv; 2024 Jun; 8(12):3109-3119. PubMed ID: 38513135
[TBL] [Abstract][Full Text] [Related]
3. Importance of the C-Reactive Protein to Albumin Ratio in the Diagnosis and Prognosis of Mycosis Fungoides.
Taş-Aygar G; Ataş H; Gönül M; Kartal SP
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810087
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
5. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
6. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides.
Porkert S; Griss J; Hudelist-Venz M; Steiner I; Valencak J; Weninger W; Brunner PM; Jonak C
J Dtsch Dermatol Ges; 2024 Apr; 22(4):532-550. PubMed ID: 38444271
[TBL] [Abstract][Full Text] [Related]
8. Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials.
Farabi B; Seminario-Vidal L; Jamgochian M; Akay BN; Atak MF; Rao BK; Karagaiah P; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 Jul; 21(7):2742-2748. PubMed ID: 34687485
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
10. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
